AbbVie to develop, sell I-Mab's lead cancer drug
-Drugmaker AbbVie Inc has entered an agreement to develop and sell Chinese biotech company I-Mab’s lead cancer drug, the companies said on Friday.
(Reuters) – Drugmaker AbbVie Inc has entered an agreement to develop and sell Chinese biotech company I-Mab’s lead cancer drug, the companies said on Friday.
AbbVie will pay I-Mab $180 million in upfront payment and an additional $1.74 billion in milestone payments for lemzoparlimab, the companies said.
(Reporting by Trisha Roy in Bengaluru; Editing by Arun Koyyur)
ANA NEWS WIRE Disclaimer:
The African News Agency (ANA) is a news wire service and therefore subscribes to the highest standards of journalism as it relates to accuracy, fairness and impartiality.
ANA strives to provide accurate, well sourced and reliable information across Text, Images and Video. Where errors do appear, ANA will seek to correct these timeously and transparently.
The ANA platform also contains news and information from third party sources. ANA has sought to procure reliable content from trusted news sources but cannot be held responsible for the accuracy and opinions provided by such sources on the ANA platform or linked sites.
The content provided for on the ANA News Wire platform, both through the ANA news operation and via its third party sources, are for the sole use of authorised subscribers and partners. Unauthorised access to and usage of ANA content will be subject to legal steps. ANA reserves its rights in this regard.
ANA makes every effort to ensure that the website is up and running smoothly at all times, however ANA does not take responsibility for, and will not be held liable for times when the website is temporarily unavailable due to technical issues that are beyond our control.